AU697882B2 - Methods for measuring telomere length - Google Patents
Methods for measuring telomere lengthInfo
- Publication number
- AU697882B2 AU697882B2 AU62724/96A AU6272496A AU697882B2 AU 697882 B2 AU697882 B2 AU 697882B2 AU 62724/96 A AU62724/96 A AU 62724/96A AU 6272496 A AU6272496 A AU 6272496A AU 697882 B2 AU697882 B2 AU 697882B2
- Authority
- AU
- Australia
- Prior art keywords
- telomere
- primer
- dna
- probe
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108091035539 telomere Proteins 0.000 title claims description 304
- 102000055501 telomere Human genes 0.000 title claims description 302
- 210000003411 telomere Anatomy 0.000 title claims description 299
- 238000000034 method Methods 0.000 title claims description 170
- 239000000523 sample Substances 0.000 claims description 129
- 108020004414 DNA Proteins 0.000 claims description 119
- 108091081400 Subtelomere Proteins 0.000 claims description 52
- 230000000295 complement effect Effects 0.000 claims description 50
- 125000003729 nucleotide group Chemical group 0.000 claims description 50
- 239000002773 nucleotide Substances 0.000 claims description 48
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 108091034117 Oligonucleotide Proteins 0.000 claims description 33
- 102000039446 nucleic acids Human genes 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 19
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 19
- 239000013611 chromosomal DNA Substances 0.000 claims description 14
- 239000005546 dideoxynucleotide Substances 0.000 claims description 11
- 239000011541 reaction mixture Substances 0.000 claims description 9
- 101710163270 Nuclease Proteins 0.000 claims description 6
- 238000001502 gel electrophoresis Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 183
- 239000013615 primer Substances 0.000 description 158
- 210000000349 chromosome Anatomy 0.000 description 69
- 239000000047 product Substances 0.000 description 50
- 238000005259 measurement Methods 0.000 description 37
- 201000010099 disease Diseases 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 230000002062 proliferating effect Effects 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 21
- 230000003321 amplification Effects 0.000 description 18
- 238000003199 nucleic acid amplification method Methods 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 239000000499 gel Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 16
- 108010017842 Telomerase Proteins 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- HDRRAMINWIWTNU-PRJDIBJQSA-N [[(5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CCC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-PRJDIBJQSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 9
- 230000036425 denaturation Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 description 8
- 230000032823 cell division Effects 0.000 description 8
- 108091092356 cellular DNA Proteins 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 8
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 8
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 8
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000003362 replicative effect Effects 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 238000000137 annealing Methods 0.000 description 7
- 230000003822 cell turnover Effects 0.000 description 7
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000002987 primer (paints) Substances 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 210000001082 somatic cell Anatomy 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108010061982 DNA Ligases Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000031864 metaphase Effects 0.000 description 6
- -1 nucleoside triphosphates Chemical class 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 5
- 108010006785 Taq Polymerase Proteins 0.000 description 5
- 239000007984 Tris EDTA buffer Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 239000002751 oligonucleotide probe Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000004904 shortening Methods 0.000 description 5
- 239000001226 triphosphate Substances 0.000 description 5
- 235000011178 triphosphate Nutrition 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 201000010374 Down Syndrome Diseases 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 206010044688 Trisomy 21 Diseases 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000010094 cellular senescence Effects 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000013616 RNA primer Substances 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003277 telomerase inhibitor Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010063493 Premature ageing Diseases 0.000 description 2
- 208000032038 Premature aging Diseases 0.000 description 2
- 101710086015 RNA ligase Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 229940123582 Telomerase inhibitor Drugs 0.000 description 2
- 241000223892 Tetrahymena Species 0.000 description 2
- 206010043390 Thalassaemia alpha Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 201000006288 alpha thalassemia Diseases 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 210000003090 iliac artery Anatomy 0.000 description 2
- 210000003111 iliac vein Anatomy 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003426 interchromosomal effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000008943 replicative senescence Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical group C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- RURLVUZRUFHCJO-UHFFFAOYSA-N Chromomycin A3 Natural products COC(C1Cc2cc3cc(OC4CC(OC(=O)C)C(OC5CC(O)C(OC)C(C)O5)C(C)O4)c(C)c(O)c3c(O)c2C(=O)C1OC6CC(OC7CC(C)(O)C(OC(=O)C)C(C)O7)C(O)C(C)O6)C(=O)C(O)C(C)O RURLVUZRUFHCJO-UHFFFAOYSA-N 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000006143 Gilbert reaction Methods 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 238000010478 Prins reaction Methods 0.000 description 1
- 208000007932 Progeria Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003391 densitometric scan Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940079920 digestives acid preparations Drugs 0.000 description 1
- PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical compound OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 108010057210 telomerase RNA Proteins 0.000 description 1
- 230000033863 telomere maintenance Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US479916 | 1990-02-14 | ||
| US08/479,916 US5741677A (en) | 1995-06-07 | 1995-06-07 | Methods for measuring telomere length |
| PCT/US1996/010035 WO1996041016A1 (en) | 1995-06-07 | 1996-06-06 | Methods for measuring telomere length |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6272496A AU6272496A (en) | 1996-12-30 |
| AU697882B2 true AU697882B2 (en) | 1998-10-22 |
Family
ID=23905964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU62724/96A Expired AU697882B2 (en) | 1995-06-07 | 1996-06-06 | Methods for measuring telomere length |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US5741677A (enExample) |
| EP (1) | EP0774014A4 (enExample) |
| JP (2) | JP4294092B2 (enExample) |
| AU (1) | AU697882B2 (enExample) |
| CA (1) | CA2196898C (enExample) |
| MX (1) | MX9700950A (enExample) |
| WO (1) | WO1996041016A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE362546T1 (de) | 1995-10-12 | 2007-06-15 | Lansdorp Peter M | Verfahren zum nachweis von mehrfachkopien einer wiederholungssequenz in einem nukleinsäuremolekül |
| WO1998000537A1 (en) | 1996-07-01 | 1998-01-08 | Universite De Sherbrooke | Composition and methods for modulating the length of telomeres |
| FI990655A7 (fi) | 1996-10-01 | 1999-06-01 | Geron Corp | Ihmistelomeraasin katalyyttinen alayksikkö |
| US6117634A (en) * | 1997-03-05 | 2000-09-12 | The Reagents Of The University Of Michigan | Nucleic acid sequencing and mapping |
| US6197557B1 (en) * | 1997-03-05 | 2001-03-06 | The Regents Of The University Of Michigan | Compositions and methods for analysis of nucleic acids |
| US5871926A (en) * | 1997-04-21 | 1999-02-16 | The University Of New Mexico | Sensitive method for measurement of telomeric DNA content in human tissues |
| JP4013333B2 (ja) * | 1998-06-05 | 2007-11-28 | 株式会社Ｂ＆Ｃラボラトリーズ | 皮膚の老化度の測定方法および測定用キット |
| US7981599B1 (en) | 1998-07-31 | 2011-07-19 | Boston Probes, Inc. | Non-nucleic acid probes, probe sets, methods and kits pertaining to the detection of individual human chromosomes X, Y, 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 16, 17, 18 and 20 as 13/21 as a pair |
| US7270958B2 (en) | 1998-09-10 | 2007-09-18 | The Regents Of The University Of Michigan | Compositions and methods for analysis of nucleic acids |
| US6280947B1 (en) | 1999-08-11 | 2001-08-28 | Exact Sciences Corporation | Methods for detecting nucleotide insertion or deletion using primer extension |
| US6503718B2 (en) | 1999-01-10 | 2003-01-07 | Exact Sciences Corporation | Methods for detecting mutations using primer extension for detecting disease |
| US8114850B2 (en) * | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| US7314926B1 (en) | 1999-04-08 | 2008-01-01 | Antisoma Research Limited | Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin |
| US20080318889A1 (en) * | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| US7960540B2 (en) * | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| US20080318890A1 (en) * | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| WO2000074667A2 (en) * | 1999-06-04 | 2000-12-14 | Au Jessie L S | Compositions active in telomere damage comprising a taxane and telomerase inhibitor |
| US6995145B1 (en) | 1999-06-04 | 2006-02-07 | Au Jessie L-S | Methods and compositions for modulating drug activity through telomere damage |
| GB0005281D0 (en) * | 2000-03-07 | 2000-04-26 | Secr Defence | Analytical method |
| GB0009784D0 (en) * | 2000-04-20 | 2000-06-07 | Simeg Limited | Methods for clinical diagnosis |
| WO2003000927A2 (en) * | 2001-06-23 | 2003-01-03 | University Of Wales College Of Medicine | Method for the determination of telomere length |
| US20030124549A1 (en) * | 2001-10-11 | 2003-07-03 | Xerox Corporation | Devices and methods for detecting genetic sequences |
| DE10161829B4 (de) * | 2001-12-15 | 2006-02-16 | Peter Lahnert | Neue Methode zur Bestimmung der Telomerlänge und ihre Verwendung zur Abschätzung des Lebensalters |
| JP4515767B2 (ja) * | 2002-01-31 | 2010-08-04 | ユニバーシティ・オブ・ユタ | 非標的核酸依存性増幅の低減：反復核酸配列の増幅 |
| WO2003071252A2 (en) | 2002-02-15 | 2003-08-28 | Exact Sciences Corporation | Methods for analysis of molecular events |
| US6916621B2 (en) | 2002-03-27 | 2005-07-12 | Spectral Genomics, Inc. | Methods for array-based comparitive binding assays |
| US20040234961A1 (en) * | 2002-04-22 | 2004-11-25 | Fordyce Colleen A. | Telomere length determination and applications |
| GB0214842D0 (en) * | 2002-06-27 | 2002-08-07 | Simeg Ltd | Diagnostic method |
| AU2003284234A1 (en) * | 2002-10-16 | 2004-05-04 | Women And Infants Hospital Of Rhode Island, Inc. | Methods of assessing the risk of reproductive failure by measuring telomere length |
| KR100479264B1 (ko) * | 2002-11-01 | 2005-03-28 | 한국전자통신연구원 | 주기적 가열과 냉각을 통한 혼성화 방법 및 이를 사용하는폴리뉴클레오타이드 검출 장치 |
| EP2474822A1 (en) | 2003-01-24 | 2012-07-11 | University of Utah | Methods of predicting mortality risk by determining telomere length |
| WO2004106490A2 (en) * | 2003-05-28 | 2004-12-09 | The Johns Hopkins University | NOVEL METHODS FOR FINDING MUTATIONS CAUSED BY THE INSERTION OF REPETEAD DNAs |
| US20080108057A1 (en) * | 2004-06-22 | 2008-05-08 | Griffith Jeffrey K | Allelic imbalance in the diagnosis and prognosis of cancer |
| WO2006026654A2 (en) | 2004-08-27 | 2006-03-09 | Exact Sciences Corporation | Method for detecting a recombinant event |
| US9109256B2 (en) | 2004-10-27 | 2015-08-18 | Esoterix Genetic Laboratories, Llc | Method for monitoring disease progression or recurrence |
| US9777314B2 (en) | 2005-04-21 | 2017-10-03 | Esoterix Genetic Laboratories, Llc | Analysis of heterogeneous nucleic acid samples |
| US20100291560A1 (en) * | 2007-03-27 | 2010-11-18 | The Johns Hopkins University | Methods and compositions for diagnosis and treatment of dyskeratosis congenita and related disorders |
| EP2191013A1 (en) * | 2007-08-10 | 2010-06-02 | Tina Holding APS | Method for estimating telomere length |
| US20090131351A1 (en) * | 2007-11-16 | 2009-05-21 | Antisoma Research Limited | Methods, compositions, and kits for modulating tumor cell proliferation |
| WO2009138117A1 (en) * | 2008-05-12 | 2009-11-19 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Methods and reagents for the determination of telomere length in a semi-automatic manner of every single cell in a immobilized cell population |
| US8084203B2 (en) | 2008-05-12 | 2011-12-27 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Methods for the determination of telomere length in a semi-automatic manner of every single cell in a immobilized cell population |
| US20090298709A1 (en) * | 2008-05-28 | 2009-12-03 | Affymetrix, Inc. | Assays for determining telomere length and repeated sequence copy number |
| PT3029154T (pt) | 2008-10-17 | 2017-12-06 | Geron Corp | Método para identificação de sensibilidade de um paciente à terapia de inibição da telomerase |
| CA2748265C (en) | 2008-12-22 | 2018-04-03 | University Of Utah Research Foundation | Monochrome multiplex quantitative pcr |
| CN102791877A (zh) * | 2009-11-06 | 2012-11-21 | 酶学有限公司 | 使用双链核酸复合物与耐热聚合酶用于合成脱氧核糖核苷酸链的组合物和方法 |
| US20130217585A1 (en) * | 2010-08-25 | 2013-08-22 | The Trustees Of The University Of Columbia In The City Of New York | Quantitative Total Definition of Biologically Active Sequence Elements |
| US20120196284A1 (en) * | 2010-12-16 | 2012-08-02 | University Of Medicine And Dentistry Of New Jersey | Method of Measuring Telomere Length |
| RU2508407C9 (ru) * | 2012-10-10 | 2014-05-20 | Елена Андреевна Чирясова | Способ количественной оценки терминальных нуклеотидов g-цепи теломерной днк человека с помощью полимеразной цепной реакции и дуплекс-специфического анализа, наборы синтетических олигонуклеотидных праймеров и зондов для осуществления этого способа |
| US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| CA3176825A1 (en) | 2013-03-15 | 2014-09-18 | Elixirgen Therapeutics, Inc. | Methods of using zscan4 for treating a disease or condition associated with a karyotype abnormality |
| EP2999800B1 (en) | 2013-05-22 | 2019-09-25 | Telomere Diagnostics Inc. | Measures of short telomere abundance |
| JP2016537345A (ja) | 2013-11-13 | 2016-12-01 | ノバルティス アーゲー | 免疫応答を増強するためのｍＴＯＲ阻害剤 |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| KR102255304B1 (ko) | 2014-09-26 | 2021-05-24 | 삼성전자주식회사 | 텔로미어 증폭 방법 |
| GB201418144D0 (en) * | 2014-10-14 | 2014-11-26 | Univ Cardiff | High throughput sequencing |
| CA2971169A1 (en) | 2014-12-30 | 2016-07-07 | Telomere Diagnostics, Inc. | Multiplex quantitative pcr |
| WO2016149612A2 (en) * | 2015-03-19 | 2016-09-22 | The Johns Hopkins University | Assay for telomere length regulators |
| CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| CN106755429A (zh) * | 2016-12-27 | 2017-05-31 | 上海三誉生物科技有限公司 | 一种精确测量人群端粒长度的方法 |
| IL303660A (en) | 2017-05-02 | 2023-08-01 | Revolution Medicines Inc | Rapamycin analogs as mtor inhibitors |
| EP3676609A4 (en) * | 2017-09-01 | 2021-06-02 | Children's Medical Research Institute | TELOMERES EVALUATION PROCESS |
| US10098922B1 (en) | 2017-11-30 | 2018-10-16 | Optigenex, Inc. | Increasing telomere length in a cell |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| CA3098692A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |
| WO2019212991A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mtor inhibitors |
| EP3674418A1 (en) * | 2018-12-26 | 2020-07-01 | Life Length S.L. | Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases |
| WO2021025935A1 (en) * | 2019-08-02 | 2021-02-11 | Georgetown University | Dna-fish method for measurement of telomere length |
| AU2023275778A1 (en) | 2022-05-25 | 2024-12-12 | Revolution Medicines, Inc. | Methods of treating cancer with an mtor inhibitor |
| CN117230169B (zh) * | 2023-11-13 | 2024-02-13 | 元码基因科技（北京）股份有限公司 | 用于长片段端粒序列测序的接头、预文库及其构建方法 |
| CN117248003B (zh) * | 2023-11-13 | 2024-04-12 | 元码基因科技（北京）股份有限公司 | 用于完整端粒扩增子测序的组合物、预文库及其构建方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737454A (en) * | 1983-07-14 | 1988-04-12 | Molecular Diagnostics, Inc. | Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays |
| US5629154A (en) * | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| US5489508A (en) * | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| IL107150A0 (en) * | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
| WO1995013382A1 (en) * | 1993-11-12 | 1995-05-18 | Geron Corporation | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| EP0787203A1 (en) * | 1994-10-21 | 1997-08-06 | Zeneca Limited | Method for characterising variability in telomere dna by pcr |
-
1995
- 1995-06-07 US US08/479,916 patent/US5741677A/en not_active Expired - Lifetime
-
1996
- 1996-06-06 MX MX9700950A patent/MX9700950A/es unknown
- 1996-06-06 JP JP50217097A patent/JP4294092B2/ja not_active Expired - Lifetime
- 1996-06-06 CA CA002196898A patent/CA2196898C/en not_active Expired - Lifetime
- 1996-06-06 EP EP96921515A patent/EP0774014A4/en not_active Withdrawn
- 1996-06-06 AU AU62724/96A patent/AU697882B2/en not_active Expired
- 1996-06-06 WO PCT/US1996/010035 patent/WO1996041016A1/en not_active Ceased
- 1996-06-07 US US08/660,402 patent/US5834193A/en not_active Expired - Lifetime
-
2007
- 2007-12-20 JP JP2007329366A patent/JP2008119005A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU6272496A (en) | 1996-12-30 |
| EP0774014A4 (en) | 2002-01-02 |
| CA2196898C (en) | 2007-10-30 |
| WO1996041016A1 (en) | 1996-12-19 |
| US5741677A (en) | 1998-04-21 |
| JP4294092B2 (ja) | 2009-07-08 |
| EP0774014A1 (en) | 1997-05-21 |
| MX9700950A (es) | 1998-01-31 |
| US5834193A (en) | 1998-11-10 |
| CA2196898A1 (en) | 1996-12-19 |
| JP2008119005A (ja) | 2008-05-29 |
| JPH10507085A (ja) | 1998-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU697882B2 (en) | Methods for measuring telomere length | |
| MXPA97000950A (en) | Methods to measure the length of a clip | |
| US5688643A (en) | Method of nucleic acid-differentiation and assay kit for nucleic acid differentiation | |
| US5925517A (en) | Detectably labeled dual conformation oligonucleotide probes, assays and kits | |
| US7306916B2 (en) | Methods for detecting chromosome aberrations | |
| JP2002505117A (ja) | チモーゲン性核酸検出方法、および関連分子およびキット | |
| JPH11504517A (ja) | オリゴヌクレオチドの化学結合による核酸検出及び増幅 | |
| WO1994028178A1 (en) | In-situ hybridization probes for identification and banding of specific human chromosomes and regions | |
| EP1585974A4 (en) | PROCEDURE FOR PREDICTING MORTAL RISK BY DETERMINING THE TELEPHONE LENGTH | |
| CA2117431A1 (en) | Process for amplifying detecting and cloning gc-rich dna sequences | |
| US6803201B2 (en) | Compositions and methods for polynucleotide sequence determination | |
| KR102019800B1 (ko) | 리덕션 프로브를 이용한 유전자의 메틸화 검출 방법, 검출 키트 및 pcr 장치 | |
| EP0944740A2 (en) | Assay for detecting apoptotic cells | |
| KR102370550B1 (ko) | Egfr 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트 | |
| US6979541B1 (en) | Methods for identifying chromosomal aneuploidy | |
| US8367814B2 (en) | Assay for BCR/ABL gene rearrangement | |
| JPH11507839A (ja) | テロメラーゼ活性検定 | |
| WO1996000234A1 (en) | Centromere hybridization probes | |
| KR20200087726A (ko) | Tert 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트 | |
| US8637654B1 (en) | Messenger RNA profiling: body fluid identification using multiplex real time-polymerase chain reaction (q-PCR) | |
| JP3942079B2 (ja) | 核酸増幅時の外因性コントロール、内部コントロールのための方法 | |
| JP3401722B2 (ja) | 核酸ハイブリッド形成アッセイにおける、またはそれに関する改良 | |
| KR20200087725A (ko) | Jak2 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트 | |
| JP2982304B2 (ja) | 核酸の識別方法及び核酸の識別用検査セット | |
| EP1606389B1 (en) | Methods for polynucleotide sequence detection |